The agency, expressing concerns about hallucinations, suicidal thoughts and psychotic and violent behavior associated with methylphenidate products, says it plans to make labeling changes for that class of drugs used to treat attention deficit hyperactivity disorder. Those include Johnson & Johnson's Concerta and Ritalin from Novartis. The agency said it also is reviewing adverse event reports on Eli Lilly's Strattera and Shire's Adderall. Company representatives were not available for comment.
Published in Brief: